Officer Gregory Keenan Files Intent to Sell $54.1M in Aurinia Pharmaceuticals Shares
AUPH has more than doubled off its 52-week low of $7.285.
Summary
An officer of Aurinia Pharmaceuticals intends to sell $54.1 million in shares, acquired through option exercise, representing a significant disposition.
Key Events · Ownership and Investor Activity · AUPH
-
Officer Files Intent to Sell Shares
Gregory Keenan, an officer of Aurinia Pharmaceuticals, filed a Form 144 to sell 25,000 shares of common stock.
-
Significant Value of Intended Sale
The proposed sale has an approximate market value of $54.1 million, representing about 2.73% of the company's market capitalization.
-
Shares Acquired via Option Exercise
The shares to be sold were acquired through the exercise of options under a registered plan on the same day as the filing.
Analysis · AUPH · Life Sciences
Gregory Keenan, an officer of Aurinia Pharmaceuticals, has filed a Form 144 indicating an intent to sell approximately $54.1 million worth of common stock. This significant disposition, representing about 2.73% of the company's market capitalization, stems from the exercise of options under a registered plan. The substantial size of the intended sale by a current officer could be interpreted negatively by investors, suggesting a desire to monetize a large portion of their holdings.
At the time of this filing, AUPH was trading at $15.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.